A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This Window Of Opportunity clinical trial will examine the immunologic effects of the study
agent HB-201 in the head and neck or cervical cancer, when administered either by IT
injection or by IV route.